INSOMA BIO, INC.
Durham, NC · Founded 2018 · CIK 0001814250 · Medtech · Private
Recombinant protein-based biopolymer engineered from human elastin to enhance fat graft survival and shape retention in craniofacial reconstruction
insomabio.com →- Grants
- $6.6M
- 10 awards
- Sector median: 1
- Raised
- $3.3M
- 4 Form D · Oct 2025
- 12 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 8
- 0 granted · 8 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · A recombinant matrix to improve autologous tissue grafts | $254,627 | |
| Private capital raised | Form D · SEC | $202,000 | |
| Private capital raised | Form D · SEC | $50,000 | |
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: An Injectable Protein Matrix to Enhance the Stability of Autologous Fat Grafts | $252,992 | |
| Federal grant | Department of Health and Human Services · Phase I · Fully defined matrices for organoid culture | $290,768 | |
| Federal grant | Department of Health and Human Services · Phase II · A recombinant matrix to improve autologous tissue grafts | $1,972,696 | |
| Federal grant | Department of Health and Human Services · Phase I · A recombinant elastin skin substitute for the treatment of burns | $282,373 | |
| Federal grant | Department of Health and Human Services · Phase I · Arecombinant elastin skin substitute for the treatment of burns | $282,373 | |
| Private capital raised | Form D · SEC | $1,105,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A recombinant matrix to improve autologous tissue grafts | $1,035,879 | |
| Federal grant | National Science Foundation · Phase II · SBIR Phase II:An Injectable Protein Matrix to Enhance the Stability of Autologous Fat Grafts | $1,673,065 | |
| Federal grant | Department of Health and Human Services · Phase I · Enhancing Peripheral Nerve Repair with an Injectable Recombinant Polypeptide Scaffold | $296,151 | |
| Federal grant | Department of Health and Human Services · Phase I · An off the shelf alternative to fat transfer for soft tissue repair | $293,983 | |
| Private capital raised | Form D · SEC | $1,925,572 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1374 | Milagen, Inc. | — | $6.6M |
| 1375 | CISION VISION, INC. | — | — |
| 1376 | Metric Medical Devices, Inc. | — | $4.4M |
| 1377 | INSOMA BIO, INC. | — | $3.3M |
| 1378 | WaveSense, Inc. | — | $858K |
| 1379 | CROOKES RESEARCH LLC | — | — |
| 1380 | RESOLV TECHNOLOGY INC | — | $5.7M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- June AlmenoffDirector
- Juliana BlumDirector
- Heather BrennanDirector
- Ashutosh ChilkotiDirector · Executive Officer
- Stefan RobertsDirector · Executive Officer
Patents
- Fully Defined Matrices For Organoid Cultureapplication
- Compositions And Methods For Generating Protein-based Sheets For Tissue Engineeringapplication
- Protein Matrix Composition For Hard And Soft Tissue Matrix Repair, Reconstruction, And/or Augmentationapplication
- Composition And Methods For A Matrix Fillerapplication
- Compositions And Methods For Nerve Repairapplication
- Compositions And Methods For Generating Protein-based Sheets For Tissue Engineeringapplication
- Fully Defined Matrices For Organoid Cultureapplication
- Fully Defined Matrices For Organoid Cultureapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.